Eris Lifesciences Limited
All news and filings related to Eris Lifesciences Limited.
View all news & filings- Medium impact
Eris Lifesciences: Executive Director & COO Krishnakumar Vaidyanathan Resigns
Mr. Krishnakumar Vaidyanathan has resigned as Executive Director & COO of Eris Lifesciences. His resignation is effective September 30, 2026, as he seeks opportunities outside the organization. The company acknowledged his contributions.
Read the summary - Low impact
Eris Lifesciences Clarifies Loan Value Amidst News Reports
Eris Lifesciences Limited clarified news reports concerning its loan value. The company stated that the correct loan value is as per its previous official disclosure. Investors are advised to rely on exchange-disseminated information.
Read the summary - Low impact
Eris Lifesciences Secures ₹45 Crore Term Loan from Axis Bank
Eris Lifesciences Limited has secured a term loan of ₹45 Crores from Axis Bank Limited. The loan is intended to meet other liabilities. The agreement was executed on 09 September 2026, with Axis Bank holding a charge on the company's brands as security. This is a routine financial adjustment.
Read the summary - Low impact
Eris Lifesciences to Meet Bank of India Mutual Fund on Sept 10, 2026
Eris Lifesciences Limited management will meet with Bank of India Mutual Fund on September 10, 2026. The in-person meeting is scheduled for 3:30 PM IST. Mr. Krishnakumar Vaidyanathan will represent the company. Discussions will be limited to publicly available information.
Read the summary - Low impact
Eris Lifesciences Announces 20th AGM on Sept 25, 2026, with E-voting Facility
Eris Lifesciences will hold its 20th AGM on September 25, 2026, via Video Conference. The record date is September 18, 2026. Remote e-voting is open from September 22 to September 24, 2026. All relevant documents are available on the company and stock exchange websites.
Read the summary - Low impact
Eris Lifesciences Announces 20th AGM on September 25, 2026
Eris Lifesciences Limited will hold its 20th Annual General Meeting (AGM) on September 25, 2026, at 11:00 AM IST via Video Conferencing. The meeting will include e-voting facilities. Annual reports and notices will be sent electronically.
Read the summary - Low impact
Eris Lifesciences to hold 20th AGM on Sep 25, 2026, via VC
Eris Lifesciences will hold its 20th AGM on September 25, 2026, via video conferencing. The agenda includes adopting FY26 financial statements and re-appointing directors. Remuneration for cost auditors for FY27 is proposed at ₹3,66,000. Mr. Sujesh Vasudevan is proposed for a second term as Independent Director.
Read the summary - Low impact
Eris Lifesciences Reappoints Mr. Sujesh Vasudevan as Independent Director; AGM on Sep 25
Eris Lifesciences' Board approved the re-appointment of Mr. Sujesh Vasudevan as Independent Director for a 5-year term starting July 25, 2027. The 20th Annual General Meeting is scheduled for September 25, 2026.
Read the summary - Low impact
Eris Lifesciences to Meet HBM Partners AG on Aug 27, 2026
Eris Lifesciences Limited management will meet with HBM Partners AG on August 27, 2026. The meeting, scheduled for 10:30 AM IST, will be in person and represented by Mr. Amit Bakshi. Discussions will be based on publicly available information.
Read the summary - Low impact
Eris Lifesciences to Participate in Investor Conferences from Aug 17
Eris Lifesciences Limited management will attend investor conferences. Mr. Krishnakumar Vaidyanathan will represent the company in a virtual meeting with Tokio Marine Asset Management on August 17, 2026, at 12:00 PM IST. Publicly available documents will be used for discussions.
Read the summary - Low impact
Eris Lifesciences Limited Schedules Investor Meetings from Aug 14, 2026
Eris Lifesciences Limited management will participate in investor meetings. A virtual one-on-one meeting with Franklin Templeton is scheduled for August 14, 2026, at 11:00 AM IST. No unpublished price-sensitive information will be disclosed.
Read the summary - Low impact
Eris Lifesciences Draws ₹64.4 Crore Working Capital Loan from Axis Bank
Eris Lifesciences Limited has drawn down a working capital term loan of ₹64.40 crore from Axis Bank. The funds are intended to meet short-term liabilities. The company confirmed that its overall debt level will remain unchanged. The loan agreement was executed on August 5, 2026.
Read the summary - Low impact
Eris Lifesciences: Transcript of Q1 FY27 Analyst and Investor Call Released
Eris Lifesciences Limited has released the transcript of its Analyst and Investor call held after announcing Q1 FY27 financial results. The transcript is available on the company's website under the financials section.
Read the summary - Low impact
Eris Lifesciences to Participate in Investor Conference on Aug 4, 2026
Eris Lifesciences management will attend an investor meeting with Bandhan Mutual Fund on August 4, 2026. The virtual meeting will be held at 4:00 PM IST.
Read the summary - Low impact
Eris Lifesciences: Q1 FY27 Earnings Call Recording Available Online
Eris Lifesciences Limited announced the availability of its Q1 FY27 earnings call recording, held on July 29, 2026. The call covered unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The recording is accessible on the company's website.
Read the summary - High impact
Eris Lifesciences Q1 FY27: Revenue ₹873 Cr, PAT ₹143 Cr, Up 13% & 14.5% YoY
Eris Lifesciences reported Q1 FY27 consolidated revenue of ₹873 crore, up 13% YoY, and PAT of ₹143 crore, up 14.5% YoY. The DBF segment revenue grew 14.2% to ₹801 crore. The company gained market share in Insulins and leads in GLP-1 prescriptions. International business revenue was ₹72 crore.
Read the summary - Medium impact
Eris Lifesciences Board Approves Q1 FY27 Financial Results and Reappoints Cost Auditors
Eris Lifesciences Limited's Board approved unaudited standalone and consolidated financial results for Q1 FY27, ending June 30, 2026. Total income was ₹875.64 crore and net profit was ₹143.32 crore. Basic EPS was ₹10.28. The company also re-appointed M/s Kiran J. Mehta & Co. as Cost Auditors for FY27.
Read the summary - Low impact
Eris Lifesciences Schedules Analyst & Investor Call for July 29, 2026
Eris Lifesciences will host an analyst and investor conference call on Wednesday, July 29, 2026, at 4:30 PM IST. This follows a board meeting to approve Q1 FY2027 unaudited financial results for the quarter ended June 30, 2026.
Read the summary - Low impact
Eris Lifesciences files SEBI Regulation 74(5) certificate for Q1 FY27
Eris Lifesciences Limited has submitted its quarterly confirmation certificate under SEBI Regulation 74(5) for the period ending June 30, 2026. The certificate was issued by the company's RTA, MUFG Intime India Private Limited, confirming the processing of dematerialised securities.
Read the summary - High impact
Eris Lifesciences Presents Corporate Update Highlighting Growth and Expansion
Eris Lifesciences presented its corporate update highlighting strong performance in branded formulations and international business. The company reported FY26 revenue of ₹3,129 crore and EBITDA of ₹1,120 crore. Strategic acquisitions have expanded its presence, with over ₹4,300 crore invested between FY23-FY26. Eris aims for continued growth in its diabesity pipeline and international markets.
Read the summary - Low impact
Eris Lifesciences Fined ₹8.49 Lakh by BSE & NSE for Board Composition Non-Compliance
Eris Lifesciences Limited was fined ₹4,24,800 each by BSE and NSE for non-compliance with board composition rules for Q4FY26. The issue arose from a temporary board vacancy, which has since been rectified as of March 14, 2026. The total penalty is ₹8,49,600.
Read the summary - Low impact
Eris Lifesciences Promoter Group Declares 53.92% Stake and No New Encumbrances as of March 31, 2026
Eris Lifesciences Promoter Group, represented by Kaushal Kamlesh Shah, declared holding 7,47,08,744 equity shares (53.92%) as of March 31, 2026. No new encumbrances were made during the financial year, beyond previously disclosed ones.
Read the summary - Low impact
Eris Lifesciences Q4FY26 Analyst Call Transcript Available
Eris Lifesciences Limited has released the transcript of its Q4FY26 Analyst and Investor call. The call discussed financial results for the quarter and year ended March 31, 2026. The transcript is available on the company's website.
Read the summary - Low impact
Eris Lifesciences: Shareholders Approve Appointment of Vineet Varma as Independent Director
Eris Lifesciences Limited shareholders approved the appointment of Mr. Vineet Varma as an Independent Director via postal ballot. The remote e-voting period concluded on May 23, 2026. The resolution passed with 99.92% of valid votes in favour.
Read the summary - Low impact
Eris Lifesciences to participate in investor meet on May 29, 2026
Eris Lifesciences Limited management will attend an investor meeting with Franklin Templeton on May 29, 2026. The virtual meeting, scheduled for 10:30 AM IST, will involve Mr. Krishnakumar Vaidyanathan. No unpublished price-sensitive information will be discussed.
Read the summary - Low impact
Eris Lifesciences: Q4 FY26 Earnings Call Recording Available Online
Eris Lifesciences Limited announced that the recording of its Q4 FY26 earnings conference call is now available. The call, held on May 20, 2026, covered the audited consolidated and standalone financial results for the quarter and year ended March 31, 2026.
Read the summary - High impact
Eris Lifesciences FY26 Results: DBF Revenue Up 11%, EBIDTA Up 12%
Eris Lifesciences reported FY26 DBF revenue of ₹2,778 crore (up 11%) and EBIDTA of ₹1,026 crore (up 12%), with margins at 37%. Consolidated FY26 revenue reached ₹3,129 crore (up 8.1%) and EBIDTA ₹1,120 crore (up 10.1%). The new Semaglutide brand, SUNDAE, shows strong initial performance. FY27 guidance includes 1.3x CVM growth for DBF revenue and 18-20% for international business.
Read the summary - Medium impact
Eris Lifesciences declares interim dividend of ₹7.21 per share; approves FY26 results
Eris Lifesciences announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company declared an interim dividend of ₹7.21 per share for FY27. The record date for the dividend is May 29, 2026.
Read the summary - Low impact
Eris Lifesciences to Hold Analyst & Investor Call on May 20, 2026
Eris Lifesciences will host an analyst and investor call on May 20, 2026, at 4:30 PM IST. The call will discuss the standalone and consolidated financial results for the quarter and year ended March 31, 2026. Pre-registration for the Zoom webinar is required.
Read the summary - Medium impact
India Ratings Affirms Eris Lifesciences' Bank Loan Facilities at 'IND AA'; Outlook Stable
India Ratings has affirmed Eris Lifesciences' Long-term Issuer Rating and bank facilities at 'IND AA' with a Stable outlook. The company's EBITDA rose to ₹8.5 billion in 9MFY26, and net leverage improved to 2.2x in FY25. Ind-Ra expects sustained growth via inorganic expansion.
Read the summary - Low impact
Eris Lifesciences Limited: Newspaper Publication Regarding Postal Ballot Notice
Eris Lifesciences Limited published a notice regarding a postal ballot for the appointment of Mr. Vineet Varma as an independent Director. E-voting is open from April 24, 2026, to May 23, 2026. The notice was dispatched via email on April 23, 2026.
Read the summary - Low impact
Eris Lifesciences seeks shareholder approval for Vineet Varma's Independent Director appointment
Eris Lifesciences is seeking shareholder approval via postal ballot to appoint Vineet Varma as an Independent Director for a five-year term from March 14, 2026, to March 13, 2031. The e-voting period runs from April 24 to May 23, 2026. Results are expected by May 25, 2026.
Read the summary - Medium impact
Eris Lifesciences: Swiss Parenterals Units Inspected by HALMED, Croatia
Eris Lifesciences' subsidiary, Swiss Parenterals, was inspected by Croatia's HALMED from March 9-13, 2026. The company received procedural non-compliance observations for its Ahmedabad units. Eris will respond with corrective actions, expecting minimal impact on existing business but a delay in its EU-CDMO product pipeline commercialization.
Read the summary - Low impact
Eris Lifesciences files SEBI Depository Certificate for Q4FY26
Eris Lifesciences Limited submitted a confirmation certificate for Q4FY26 under SEBI regulations. The company's RTA, MUFG Intime India, confirmed processing of dematerialized securities and updates to the register of members within prescribed timelines.
Read the summary - Medium impact
Eris Lifesciences Completes Acquisition of Velbiom Probiotics Business
Eris Lifesciences Limited announced the closure of its acquisition of the Probiotics Business of Velbiom Probiotics Private Limited. This follows an earlier intimation dated March 20, 2026. The company confirmed the transaction has achieved closure.
Read the summary - Low impact
Eris Lifesciences Closes Trading Window from April 1, 2026, for FY26 Audited Results
Eris Lifesciences will close its trading window from April 1, 2026. The window will reopen 48 hours after the announcement of audited financial results for the quarter and fiscal year ending March 31, 2026. Designated persons and their relatives are prohibited from trading securities during this period.
Read the summary - Medium impact
Eris Lifesciences Partners Natco Pharma for Semaglutide Launch in India
Eris Lifesciences partners with Natco Pharma for the commercialisation of Semaglutide in India. Natco Pharma has received CDSCO approval for generic semaglutide, with a launch expected in March 2026. This strategic move aims to strengthen Eris's diabetes and metabolic care portfolio.
Read the summary - Medium impact
Eris Lifesciences Acquires Probiotics Business from Velbiom for ₹50 Crore
Eris Lifesciences acquired Velbiom Probiotics' branded probiotic products for ₹50 crore on a slump sale basis. The acquired business had revenues of ₹16.02 crore in 9M FY26. The deal was approved by the board on March 20, 2026.
Read the summary - Low impact
Eris Lifesciences Appoints Vineet Varma as Additional Director
Eris Lifesciences appointed Mr. Vineet Varma as Additional Director (Non-Executive, Independent). His term is for five years, effective March 14, 2026. Mr. Varma brings over 25 years of experience in wholesale banking.
Read the summary - Low impact
Eris Lifesciences to participate in Investor Conference on March 19, 2026
Eris Lifesciences Limited management will attend an investor conference on March 19, 2026. Mr. Krishnakumar Vaidyanathan will represent the company in a 1x1 in-person meeting in Mumbai at 9:30 AM. Discussions will be based on publicly available information.
Read the summary - Low impact
Eris Lifesciences to Participate in Investec India Conference on March 10, 2026
Eris Lifesciences Limited will participate in the Investec India Promoter & Founder Conference 2026 on March 10, 2026, in Mumbai. Management representatives Mr. Amit Bakshi and Ms. Kruti Raval will attend. Discussions will be based on publicly available information.
Read the summary - Low impact
Eris Lifesciences Fined ₹1.3 Lakh by BSE & NSE for Director Compliance Lapse
Eris Lifesciences Limited was fined ₹65,000 each by BSE and NSE on February 27, 2026, totaling ₹1.3 lakh. The penalty stems from non-compliance related to an Independent Director's term completion. The company is in the process of appointing a new director to address the board composition issue.
Read the summary - Low impact
Eris Lifesciences to Participate in Ajanta India Fund Investor Meet on Feb 26
Eris Lifesciences Limited management, including Mr. Krishnakumar Vaidyanathan, will attend an investor meet hosted by Ajanta India Fund on February 26, 2026, in Mumbai. The meeting is scheduled for 10:00 AM and will discuss publicly available information.
Read the summary - High impact
Eris Lifesciences Presents Corporate Presentation Highlighting Growth and Strategic Investments
Eris Lifesciences presented its corporate strategy, highlighting strong growth in anti-diabetes and insulins. Strategic acquisitions and investments total over ₹4,300 crore, expanding therapeutic and geographic reach. The company aims for accelerated EPS growth and debt reduction, targeting <1.5x Debt-to-EBITDA by Dec 2026. Key investments focus on Diabesity and Injectables.
Read the summary - Low impact
Eris Lifesciences: Transcript of Q3FY26 Analyst Call Available Online
Eris Lifesciences Limited has made the transcript of its Q3FY26 Analyst and Investor call available on its website. The call was held after the announcement of financial results for the quarter and nine months ended December 31, 2025.
Read the summary - Low impact
Eris Lifesciences to Participate in IIFL's Global Investors' Conference on Feb 25, 2026
Eris Lifesciences Limited will participate in IIFL's 17th Enterprising India Global Investors' Conference on February 25, 2026, in Mumbai. Management representatives Krishnakumar Vaidyanathan and Kruti Raval will attend. Discussions will be based on publicly available information.
Read the summary - Low impact
Eris Lifesciences: Q3 FY26 Earnings Conference Call Recording Available
Eris Lifesciences Limited has made the recording of its earnings conference call for Q3 FY26 available. The call covered financial results for the quarter and nine months ended December 31, 2025. The recording is accessible on the company's website.
Read the summary - High impact
Eris Lifesciences Q3 FY26: Revenue Rs. 807 Cr, PAT Rs. 109 Cr. DBF Growth 10%.
Eris Lifesciences reported Q3 FY26 consolidated revenue of ₹807 crore, up 11% YoY, and adjusted PAT of ₹120 crore, up 38.5% YoY. DBF revenue grew 10% to ₹696 crore. International Business revenue surged 45% to ₹111 crore. The company aims for a Net Debt to EBIDTA ratio below 1.5x by Dec 2026.
Read the summary - Medium impact
Eris Lifesciences Reports Q3 FY26 Unaudited Financial Results
Eris Lifesciences reported Q3 FY26 consolidated net profit of ₹108.83 crore, up from ₹87.06 crore in Q3 FY25. Nine-month consolidated profit was ₹368.40 crore. Standalone Q3 profit was ₹3.09 crore. The company made an exceptional provision of ₹17.24 crore due to new labor codes. Swiss Parenterals became a wholly owned subsidiary on January 16, 2026.
Read the summary - Low impact
Eris Lifesciences to hold Analyst & Investor Call on Feb 13, 2026
Eris Lifesciences Limited will host an analyst and investor conference call on February 13, 2026, at 5:30 PM IST. The call will discuss the unaudited financial results for the quarter and nine months ended December 31, 2025.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio